Stock Information
symbol line chart

PRGOPerrigo Company plc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Murray S. Kessler

Location

Michigan, USA

Exchange

NYSE

Website

https://perrigo.com

Summary

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being.

Company Info

CEO

Murray S. Kessler

Location

Michigan, USA

Exchange

NYSE

Website

https://perrigo.com

Summary

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being.

AI Insights for PRGO
2 min read

Quick Summary

Perrigo Company plc is a global provider of over-the-counter (OTC) health and wellness solutions, with major operations in North America and Europe. The company specializes in manufacturing and distributing private-label and store-brand products, primarily for leading retail customers such as Walmart and Target. Its offerings span various segments, including consumer self-care products in areas like allergy relief, smoking cessation, oral care, and infant nutrition. Perrigo's business model emphasizes operational efficiency and innovations in self-care and wellness. Its core customer base includes major retailers, pharmacy chains, and grocery stores that rely on Perrigo for affordable, high-quality health products under both house and recognized brand names.

The Bull Case

  • Perrigo’s strengths include its well-established position as a leading supplier of private-label and store-brand OTC health products, which gives it substantial leverage with major retailers in North America and Europe.
  • The company boasts a diversified product portfolio, a track record of operational efficiency, and an ability to generate strong cash flows that support a consistent dividend (with a 22-year streak of increases).
  • Its supply chain optimization and cost management programs have delivered significant savings, improving margins even amidst sales volatility.
  • Recent innovations such as the launch of OTC contraceptives and investments in formula capacity reflect Perrigo’s agility in responding to consumer needs.
  • Strong relationships with blue-chip customers enhance sales stability.

The Bear Case

  • Perrigo faces weaknesses in several challenged business segments, most notably infant formula and oral care, which have struggled with declining sales and heightened price competition.
  • The company’s frequent need to revise guidance and its recent net income pressures have weighed on investor confidence.
  • Exposure to tariff increases and foreign currency risks add further unpredictability to cost of goods sold and revenue.
  • While cost-cutting has improved margins, organic sales growth has remained sluggish.
  • The reliance on a limited number of powerful retail customers also makes Perrigo vulnerable to price negotiations and shifts in retailer strategies.

Key Risks

  • Perrigo is exposed to risks from declining sales in key categories, particularly if market competition in infant formula and oral care intensifies or lasts longer than expected.
  • Macroeconomic uncertainty—including inflation, consumer sentiment, and rising tariffs—can negatively impact demand and raise input costs.
  • Prolonged supply chain disruptions or inability to execute on cost-cutting programs may undermine margin improvements.
  • The company’s high leverage and recent guidance cuts could also affect its credit ratings and dividend sustainability over time.

What to Watch

UpcomingIn the most recent quarter, Perrigo experienced both positive and negative milestones.
UpcomingThe company saw net sales decline due to weak performance in its infant formula and oral care segments, with overall net sales dropping 3.2–4.1%, and it issued a guidance cut for the remainder of 2025.
UpcomingDespite the sales shortfall, adjusted EPS beat expectations, driven by improved gross margins and successful cost savings programs, including Project Energize and ongoing supply chain optimizations.
ExpectedFor the upcoming quarter, Perrigo anticipates ongoing challenges in its infant formula business as market competition remains intense, but expects gradual recovery in store-brand market share and further margin improvement due to ongoing operational efficiencies.

Price Drivers

  • The stock price of Perrigo is driven by its earnings performance, particularly its ability to grow organic sales and profit margins.
  • Key factors include the success of new product introductions, efficiency in supply chain management, and ability to weather competitive pressures in segments like infant formula and oral care.
  • Macroeconomic events, such as changes in consumer spending or regulatory shifts affecting OTC drug and formula markets, also play a role.
  • The impact of tariffs and currency fluctuations, as well as cost savings from restructuring and cost-cutting programs, influence profitability and investor sentiment.

Recent News

  • Recent news on Perrigo highlights a mixed performance: the company has seen persistent share losses driven by weak performance and sales misses in infant formula and oral care, leading to guidance cuts and a sharp drop in share price, earning it negative analyst ratings.
  • Despite this, Perrigo continues to invest in U.S.
  • formula manufacturing with the strategic acquisition of the Good Start brand and a Wisconsin plant from Nestlé.
  • Supply chain changes and cost-cutting initiatives have yielded material annual savings, supporting improved margins and stable or growing dividends.

Market Trends

  • In the broader market, demand for affordable and store-brand OTC health products continues to grow, as more consumers seek value amid inflation and economic uncertainty.
  • The healthcare sector is experiencing consolidation, with large companies divesting non-core units and investing in strategic categories like wellness, women’s health, and infant nutrition.
  • Regulatory changes and supply chain disruptions are top of mind, affecting costs and product availability across sectors, particularly in formula.
  • Increased interest in self-care and preventative health products benefits companies with a broad, trusted portfolio.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on PRGO

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show